A week after African ministers of health adopted a treaty for the establishment on the African Medicines Agency, an international conference held on the side of the World Health Assembly denounced the rampant and increasing issue of fake medicines in Africa, and the lack of adequate action and political will. The Benin president said Benin's efforts to fight traffickers is so far unsupported, and called developed countries to commit to the fight. Other speakers insisted on the importance of local production of medicines, and the need for biting legislation to defeat fake medicines. Continue reading ->
Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading ->
For the second year in a row, Taiwan has not been invited to participate as an observer at the World Health Assembly taking place this week. Political dissent with China borne out of a change of government in Taiwan now refusing to recognise the “One China” principle resulted in Taiwan being left out of the World Health Organization. At the opening of the Assembly, several countries supported Taiwan, including the United States. Continue reading ->
World Health Organization Director General Tedros Adhanom Ghebreyesus (“Dr Tedros”) in his first speech in his function at head of the World Health Assembly described three keys to reach the ambitious goals of the organisation. He envisioned a transformed WHO helped by a strong leadership team, called for political commitment for which he said most […] Continue reading ->
Brazil is frequently pointed to as one of the countries in which fewer pharmaceutical patents are granted. The fact that there is a low number of patents granted could lead to the conclusion that medicines can be bought under competition and that the prices would be low. However, many medicines in Brazil are bought exclusively from one producer and usually at high prices. The situation of few granted patents, but many purchases under exclusivity due to absence of competition (which can lead to higher prices), is what we are calling the ‘patent paradox in Brazil’. In the absence of granted patents, what are the factors that lead to the situation of no competition and high prices in Brazil? This is the question that we, at the accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa, aim to answer with a study currently being conducted at the Department of Medicines Policy and Pharmaceutical Services (NAF) of the Sergio Arouca National School of Public Health – ENSP/Fiocruz. Continue reading ->